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We present the first comprehensive investigation on water-soluble nanoparticles embedded into a paramagnetic shell 
and determine their properties as an MRI contrast agent.  The nanoprobes are constructed with an inorganic core 
embedded into an ultra-thin silica shell covalently linked to chelated Gd(III) ions. The chelator consists in the molecule 
DOTA and the inorganic cores are fluorescent CdSe/ZnS qdots or Au nanoparticles. Optical properties of the cores 
(fluorescence emission or plasmon position) are not affected by the neither the silica shell nor the presence of the 
chelated paramagnetic ions. The resulting complex has a diameter of 8 to 15 nm and is soluble in high ionic strength 
buffers at pH ranging from ~4 to 11, even at concentrations exceeding 50 µM. In MRI experiments at clinical field 
strengths of  60 MHz, the MRI nanoprobes posses spin-lattice (T1) and a spin-spin (T2) relaxivities of  ~1000 mM-1s-1 
and 2500 mM-1 s-1  respectively for probes having ~ 8 nm and about 16000 mM-1s-1 for 15 nm probes. The relaxivity 
has been correlated to the number of Gd(III) covalently linked to the silica shell. At 60 MHz, each bound chelated 
Gd(III) contributes by over 23 mM-1s-1 to the total T1 and by over 54 mM-1s-1 to the total T2 relaxivity respectively. The 
sensitivity of our probes is in the 100 nM range for 8-10 nm particles and reaches 10 nM for particles with 
approximately 15-18 nm in diameter, and can be improved by packing more Gd(III) on the surface. Preliminary 
dynamic contrast enhancement MRI experiments in mice reveal that silica-coated MRI probes are cleared from the 
renal system into the bladder within minutes, with no observable effects on the health of the animal.  In vivo 
biocompatibility and the ease of further functionalization should expand the range of applications beyond angiogenesis. 
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Recent years have witnessed a new age in 
fluorescence imaging driven by remarkable advances in 
detection technologies. The ability to discern fluorescent 
markers at the single molecule level is important for 
molecular imaging, in particular for monitoring signaling 
pathways in live cells or for the study of cellular 
metabolism.1 Qdots represent a new form of fluorescent 
agents that possess many of the properties to perform these 
studies.2 They have the size of a protein and can be 
programmed to acquire biological functions, they are well 
tolerated by live cells, they afford multiplexed detection 
due to their tunable emission, they are resistant to 
photobleaching, and they can be tracked at the single 
molecule level over extended periods of time. 3, 4 Thus, by 
using biologically engineered QDs, there is great potential 
for learning more about the molecular basis of certain 
diseases, such as cancer, and finding a therapeutic 
treatment. 5, 6 
For this noble cause, a big leap forward has to be 
taken to correlate the deficiency of a cell in vitro to a 
disease in vivo. Cells reside in highly structured 3D 
environments. They are sensitive to the extracellular 
matrix and to the presence of neighboring cells with which 
they make mechanical or biochemical contact. Although 
most diseases originate from the malfunction of a single 
cell, whether the disease spreads ultimately depends on 
whether the cell and its daughters can survive and 
proliferate by beating the feedback control mechanisms in 
a complex 3D multicellular organism. It is therefore 
important to know not only what happens within a single 
cell but also how cells communicate and socialize and how 
they respond to stimuli in vivo. 
In this regard, the use of bioengineered QDs is 
problematic because fluorescence has one notorious 
shortcoming: light has a penetration depth of less than a 
few millimeters in the best case. As a result, fluorescence 
is a powerful tool mainly limited to in vitro imaging. In 
vivo medical applications, such as detection of tumors or 
metastatses, or the tracking of stem cells after cell therapy 
treatment require a different set of non-invasive imaging 
probes and techniques.7-9  
Magnetic resonance imaging is a method of choice for 
in vivo visualization because of its infinite penetration 
depth and its anatomic resolution. MRI has the ability to 
map the relaxation processes of water protons in the 
sample, referred as T1 and T2 relaxation times. One of the 
powers of MRI is its ability to extract image contrast, or a 
difference in image intensity between tissues, on the basis 
of variations in the local proton environment. 
Unfortunately, intrinsic differences between tissues are 
often too small to provide distinguishable relaxation times 
for protons, and the resulting contrast between tissues is 
often too weak for a firm diagnosis. This is why exogenous 
contrast agents are often used, most notably in the form of 
small amounts of paramagnetic impurities, such as 
chelated Gd(III),10 linked to a targeting biomolecule.11 
They accelerate the T1 and T2 relaxation processes of water 
protons in their surrounding. However, even in such case, 
the contrast obtained in MRI might not be strong enough, 
because the contrast agent by itself does not provide 
enough sensitivity. Considerable efforts have focused in 
developing contrast agents with improved properties.  
The performance of a contrast agent in solution is 
measured by its relaxivity, defined as 1/Ti ~ ri *[C], i=1,2, 
where ri is the relaxivity and [C] the concentration of the 
contrast agent. The rule is that higher its relaxivity, the 
more sensitive the contrast agent. T1-contrast agents are 
agents that affect mostly the longitudinal relaxation time. 
They are usually made of chelated lanthanide ions and 
reach relaxivities of 5-50 mM-1s-1. 12 Higher relaxivities are 
obtained with T2-contrast agents, i.e. agents that affect 
mainly the transversal relaxation time, which is the most 
prominent of which are iron oxide nanoparticles. These 
particles, used in clinical trials, have sizes around 50-200 
nm in diameter. At this size range, they often exhibit a 
hysteresis curve upon application of a reversal magnetic 
field, a sign that the magnetic moment is tightly bound to 
the crystal structure. Superparamagnetic behavior (i.e. no 
hysteresis upon a switching field) is preferred for MRI 
applications. The SP regime is the realm of smaller 
magnetic nanoparticles with core sizes below ~20 nm, 
often labeled SPIO (Small Superparamagnetic Iron Oxide). 
13 Decreasing the size of the SPIO nanoparticles also leads 
to a decrease in their total magnetic moment and reduces 
their contrast power. In this work, we present and 
characterize a probe construct that reaches T1 and T2 
relaxivities of up to approximately 13’000 and ~15’000 
mM-1s-1 at clinical fields while its size is only 15-18 nm. 
Smaller constructs of size in the range of 8-10 nm exhibit 
relaxivities of approximately 1000 and 2500 mM-1 s-1.  
The construct consists in an inorganic nanoparticle 
core (fluorescent CdSe/ZnS or Au) embedded into a thin 
paramagnetic silica shell. These silica-coated scaffolds are 
about 10 nm in size and are used to covalently anchor 
multiple GdDOTA molecules. We present evidence that a 
multi-component mechanism contributes to these 
exceedingly high relaxivity values. The mechanism 
involves a large number of GdDOTA moieties, the slowing 
of tumbling rate of GdDOTA and the hydrophilicity of the 
silica surface. In fact, the number of GdDOTA moieties 
linked to the silica shell can be tuned from 20 up to 320 
and in some cases above a few thousend, and each unit 
contributes additively to the total relaxivity. Moreover, we 
observe that the T1 and T2 relaxivities per GdDOTA unit 
(or ion relaxivity) is increased by a factor of 5 and 10 
respectively when GdDOTA is bound to the silica shell 
compared to its mobile form in solution, and by a factor of 
2 and 3 respectively compared to the case when GdDOTA 
is linked to nanoparticles through a flexible, weakly 
hydrophilic phospholipids layer.  
The design of our probe can be easily extended to 
cover PET imaging, and we do not foresee any difficulty to 
enhance the capability of the silica-coated probes by 
adding a targeting mechanism. We will discuss a set of 
advantages provided by paramagnetic silica shells over 
polymeric coatings. 
 
 
2 Experimental Details 
 
2.1 Synthesis and characterization of silanized 
CdSe/ZnS QDs and Au nanocrystals coated with Gd-
DOTA 
 
In both cases, we use a three-steps process: first we grow 
a PEG-ylated silica shell containing thiol groups around 
the inorganic cores (semiconductor or metalic); second we 
synthesize paramagnetic agents made of an amine-
terminated DOTA molecules that chelates Gd(III) ions; 
third we covalently crosslink the chelated paramagnetic 
compound to silanized particles using a bifunctional cross-
linker. 
 
 
 
 
 
 
Scheme 1:  Scheme for the preparation of the paramagnetic probes. 
Gadolinium chloride is reacted with a DOTA complex under controlled 
acidic conditions at 80oC. Gd(III) is stabilized inside DOTA by hydrogen 
bonds with the carboxylic groups (dash line). Subsequently, the amine 
group, which does not take part in Gd(III) complexion, is converted into a 
maleimide group which will react with thiols on the silica-coated 
nanoparticles.  The payload of GdDOTA per nanoparticles depends on 
the surface area. It can vary from ~50 up to several hundreds. Due to this 
coupling scheme, Gd(III) is stably chelated in PBS buffer over periods 
exceeding a few months. 
 
+ sulfo-
Silanization of QDs: The synthesis and silanization of 
CdSe/ZnS QDs, or simply SiO2@QD, follow published 
procedures.14, 15 Briefly, after a priming step replacing 
TOPO surfactants on the QD surface with 
MercaptoPropyltrimethoxySilane (MPS), polymerization 
of siloxane is performed in methanol under slightly basic 
conditions. In a second step, addition of fresh MPS and 
PEG-propyltrimethoxysilane permits the introduction of 
functional (SH) and stabilizing (PEG) groups respectively 
into the forming SiO2 shell. Silane polymerization is 
quenched with trimethylchlorosilane that converts reactive 
silanol groups into methyl groups. This allows controlling 
and limiting the size of the silica shell to a thickness of a 
few nanometers. After extensive dialysis against fresh 
methanol and subsequently against 10 mM phosphate 
buffer, pH~7-7.5, silanized QD solutions are concentrated 
using centricon 100 down to optical densities greater than 
30-70 and purified further by low pressure 
chromatography using a 20 cm long, 1cm ID column filled 
with sephadex G200 or sephadex G100. Silanized qdots 
elute in a rather large band. Typically, we load 
approximately 500-700 µl of solution and collect ~ 5 ml of 
solution. Solutions of silanized Qdots are stored at room 
temperature at optical densities in the range of 3-6. 
 
Silanization of Au nanoparticles: A similar approach is 
used to silanize citrate- stabilized Au nanoparticles of 5 nm 
and 10 nm purchased at BBI International. However, in the 
case of colloidal Au, silanization is performed in an 
aqueous environment because the particles would not 
disperse in methanol. Since citrate-coated Au nanoparticles 
aggregate easily even in low ionic strength buffers, the Au 
colloids are first stabilized with a phosphine surfactant, as 
we have reported previously 16, 17. Phosphine-stabilized Au 
colloids are precipitated with ethanol and resuspended into 
a solution of 1:1000 v:v MPS in water to exchange the 
capping ligands to a thiolated siloxane. After this priming 
step, an approach similar to the QDs case is taken, with the 
growth of a shell using MPS and PEG-silane, quenching of 
the shell growth using trimethylchlorosilane. All these 
steps are however performed in water. After the procedure 
is completed, silanized Au colloids are purified using 
centrifugation. Silica-coated Au nanocrystals can be 
concentrated with a centricon 100 device to dryness. Upon 
addition of buffer, the particles resuspend spontaneously 
by a gentle shake. Such purification is performed several 
times. Despite these multiple washing steps and large 
concentrations (optical densities in the range >100), the 
plasmon peak of silanized Au colloids measured by UV-
Vis does not shift compared to the original diluted samples 
for both 5 and 10 nm colloids. We take it as a sign that 
silanization did not induce aggregation of the particles. 
The size estimates of the silanized particles are based on 
previous AFM investigations because the thin silica shell 
is hardly visible under a TEM. Based on those studies, our 
estimate is that the silica shell is about 2-3 nm thick and 
adds 4-6 nm to the particle diameter. In this study, we 
focus on ~5 nm naked CdSe/ZnS, and 5 nm and 10 nm 
citrate-stabilized Au colloids. After silanization, the 
respective sizes are ~10 nm for silanized QDs, ~10 nm for 
5-nm Au, and ~16-18 nm for 10 nm Au. 
 
Gd(III) chelation with a DOTA moiety: The synthesis of 
GdDOTA, i.e. one Gd(III) ion chelated by DOTA, is 
performed according to the procedure, adapted from 
previous reports. 18, 19 We dissolve p-NH2-Bn-DOTA, i.e. 
2-(4-Aminobenzyl)-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid, (Macrocyclics Inc., hereafter 
called simply DOTA) in water and add an aqueous 
solution of GdCl3 (Sigma-Alrich), so as to have a 1: .98 
molar mixture of DOTA:Gd(III) and ~0.2 M concentration 
in DOTA. The solution is heated a few seconds to 80oC to 
favor complexion of Gd(III) with the 
tetraazacyclododecane ring. The pH of the solution drops 
below 1. We bring the pH to 3.5-4 by adding aliquots of 
7M NaOH and heat the solution back to 80oC for a few 
minutes. At this early stage, heating produces acidification 
of the solution. Therefore, we repeated heating-adjusting 
the pH to 3.5-4 with sodium hydroxide several times (up to 
7 times) until the heating step does not produce a drop in 
pH below 3.5. At that stage, the solution is kept at 80oC for 
3 hrs. Completion of the Gd(III) chelation is confirmed by 
a colorimetric assay using Arsenazo dye (Sigma-Alrich). 
This colorimetric dye reacts to the presence of unbound 
Gd(III). The dye natural color is purple, but upon 
complexion with Gd(III), its color turns to blue. After 3 hrs, 
the GdDOTA solution is slightly yellowish and has a 
concentration of approximately 150 mM in GdDOTA, 
deduced from the initial amount of DOTA, GdCl3 and 
NaOH used. The stability of the GdDOTA has been 
studied only summarily using the colorimetric Arsenazo 
test. No Gd(III) release from the DOTA ring was observed 
over a period of several weeks.  
 
Linking GdDOTA to silanized nanoparticles: Freshly 
prepared paramagnetic GdDOTA is covalently linked to 
silanized nanoparticles to form GdDOTA-SiO2@Particle. 
First the amino group on the GdDOTA unit is converted 
into a maleimide group using sulfo-SMCC and classic 
bioconjugation conditions (pH ~ 6-6.5, SMCC:DOTA ~ 
3:1). 20 After one hour reaction, the maleimide-activated 
GdDOTA is directly reacted to silanized particles. The 
reaction is kept running for ~24 hrs at room temperature. 
Removal of unbound GdDOTA is performed by a 48 hrs 
dialysis in a 50K MWCO membrane (SpectraPor 6) 
against a bath consisting in 10 mM phosphate buffer, pH ~ 
7. We exchange the buffer bath at least 4 times during the 
dialysis period. After dialysis, the sample is further 
purified by 4 to 5 runs of centricon 100. For each run, 2 ml 
of silanized particles are condensed down to <100 µl and ~ 
1.9 ml of fresh buffer is added. After these extensive 
purification steps, we estimate that the concentration of 
unbound GdDOTA is in the fM-pM range, far too small to 
provide any signal in MRI and far smaller than a few µMs, 
the typical concentration of silanized nanoparticles. 
 
Determination of the concentration of the samples: The 
concentrations of our solutions are given in terms of 
silanized nanoparticle concentration and not in terms of 
Gd(III) present in solution. This seems to be a wise choice, 
if one considers that all Gd(III) are concentrated onto the 
nanoparticle surface and the solution is not homogenous in 
Gd(III). [at 1 µM concentration, the average distance 
between nanoparticles is ~ over 100 nm; there is no 
unbound Gd(III) in the space between nanoparticles, this 
latter being highly localized onto the nanoparticles]. 
 We measure the UV-Vis spectrum and deduce the 
concentration of the solution from the optical density at the 
exiton (for semiconductors – QDs) or plasmon (for Au 
colloids) peak using known extinction coefficients and the 
following equation: C = OD / (ε . δ), where OD is the 
optical density or amplitude of absorption at the 
exiton/plasmon peak, δ is the cuvette length (usually 1 cm 
or 2 mm) and ε is the extinction coefficient. The extinction 
coefficients are deduced from the literature (QDs) or given 
from the manufacturer (Au). We use the following 
numbers: QD exiton peak at ~ 610 nm, fluorescence 
emission at ~ 630 nm, fwhm ~38 nm, extinction 
coefficient used 620’000 M-1cm-1 following published 
reports. 21 For 5 nm an 10 nM Au colloid, both plasmon 
peaks are at 524 nm and we use ε= 1,2 x 107 M-1cm-1 for 5 
nm Au and ε= 1.06 x 108 M-1cm-1 for 10 nm Au 
respectively. These later numbers are computed from the 
concentrations given by the manufacturer and the OD of 
citrate-stabilized Au colloids measured directly out of the 
bottle. 
 
Determination of the number of Gd per silanized 
nanoparticle: After extensive purification from unbound 
GdDOTA, these samples are chemically analyzed by ICP-
MS by measuring the total amount of Gd and Cd or Au 
ions.  By assuming bulk parameters of the CdSe or Au 
lattice and the size of the nanoparticles (using tabulated 
values linking the size of the QDs to its optical properties, 
or the claimed size for Au nanocrystals), we deduce the 
number of Gd per silanized nanoparticle. The same 
samples were previousely analyzed by MRI. The number 
of GdDOTA per GdDOTA-SiO2@Particle varies from ~3 
to >300 and depends on the size of the initial nanoparticles 
and the conditions used during bioconjugation. 
 
2.2 20 MHz and 60 MHz NMR Minispec Parameters 
 
T1 and T2 relaxation time measurements were 
performed on a Bruker Minispecs operating at 20MHz and 
60MHz.  An inversion recovery pulse sequence was 
employed for T1 relaxation time measurements using a 
mono exponential fit to the recovery curve.  For each 
experiment 4 scans were collected with a recycle delay of 
15 seconds.  To obtain the recovery curve, 50 evenly 
spaced points were collected with the first point acquired 
at 5 ms.  The last time point was collected at 4000 ms for 
short T1 samples and 10,000 ms for samples with long T1 
so that each sample was allowed to fully recover. The 
receiver gain for each sample was set so that the signal 
amplitude was approximately 60%. 
T2 times were calculated from a mono exponential fit 
to a spin echo decay curve using a CPMG pulse sequence.  
Eight scans were acquired for each experiment with an 
echo time of 1ms, pulse attenuation of 6dB, and recycle 
delay of 3 seconds.  The number of echo times was varied 
between 100 points, for short T2s, and 3500 points, for 
long T2s, in order to 1acquire the full decay curve for each 
sample.  The receiver gain for each sample was set to the 
same value that was used in the T1 experiment.  
 
2.3 Bruker 2.5mm MicroImaging MRI system 
parameters  
  
All MRI experiments were performed on a Bruker 
Avance 400 MHz spectrometer equipped with a high-
resolution Micro5 microimaging system with a 25 mm rf 
coil. To obtain spin-lattice relaxation (T1) values, a Fast 
Imaging with Steady State Precession (FISP) with 
Inversion Recovery (IR) Sequence was used. The MRI 
parameters for FISP include echo time of 1.5 ms, repetition 
rate of 3.0ms, 8 averages, number of segments of 32, field-
of-view of 3x3 cm, resolution of 234x234, microns/pixel, 
flip angle (alpha) of 60°, and inversion delay (T1) of 235.5 
µsec.  To obtain spin-spin relaxation (T2) times a Multi 
Slice Multi Echo (MSME) Sequence was employed. The 
MRI parameter for MSME including number of echoes of 
32, time of echo is 13.8 ms, repetition rate of 10,000 ms, 
field-of-view of 3x3 cm, resolution of 117x117 
microns/pixel, number of averages = 1, and slice thickness 
= 1 mm.  
 
2.3 Mice imaging using a GE 1.5T MRI system 
 
3. Results  
To determine if nanoparticles embedded into a silica 
shell and linked to chelated paramagnetic ions are sensitive 
contrast agents for MRI, we first present the case of 
paramagnetic silanized semiconductor QDs samples, with 
QD core size of ~ 5nm. Subsequently, we will show that 
paramagnetic silanized metallic Au nanoparticles exhibit 
similar results. Comparison of MRI data obtained for 
GdDOTA-SiO2@P, where P represents nanoparticles of 
different nature and sizes will shed light on the nature of 
the mechanism of contrast enhancement. 
First, images were collected of 4 µM GdDOTA-
SiO2@QD and compared to control solutions. Control 
samples include: a) 4 µM SiO2@QD; b) 4 µM DOTA-
SiO2@QD lacking the activation with Gd(III); c) 10 mM 
phosphate buffer, pH ~ 7, the common buffer for these 
solutions. In the same set of experiments, unbound 
GdDOTA at concentrations ranging from 390 µM to 7350 
µM is also profiled.  This latter is a clinically approved 
contrast agent, better known under the trademark 
DOTAREM® and T1 and T2 measurements produced 
similar results to previously reported data.23 Simultaneous 
data acquisition permits a direct comparison of the 
performance of current contrast agents with our 
paramagnetic silica-coated nanoprobes. 
 
 
 
 
 
Figure 1 The spin-lattice relaxation MRI images (T1 weighted images) 
taken using a Fast Imaging with Steady State Procession (FISP) with 
inversion recovery (IR) sequence of PBS buffer, SiO2@QD, DOTA-
SiO2@QD lacking the paramagnetic load and GdDOTA-SiO2@QD, at 
400MHz and room temperature. Only the paramagnetic silica-coated 
nanoparticles exhibit a contrast.   
 
 
Figure 1 shows the spin-lattice relaxation MRI images 
(T1 weighted images).  Although qualitative differences in 
the MRI images clearly establish that only paramagnetic 
GdDOTA-SiO2@QD provide a marked contrast, a clearer 
picture emerges from quantitative evaluation of the 
longitudinal relaxation times T1, by plotting M/Mo verses 
log(τ(ms)), i.e. the residual magnetization as a function of 
the recovery time.  T1 are measured by fitting M(τ)/Mo to 
an single exponential growth curve: (M(τ)/Mo)= (1-
exp(τ/T1)).  T1 recovery curves are not shown; however the 
values are summarized in Table 1.  The GdDOTA-
SiO2@QD sample with a QD concentration of 4µM has a 
T1 of 186ms, significantly lower than the longitudinal 
relaxation times of control QD solutions where T1 was 
about 600 ms, or from buffer solutions with T1 ~ 420 ms. 
The presence of chelated Gd(III) linked to the silica shell 
produces a 3-fold decrease in T1.  
  
 
 
 
Figure 2: A spin-spin relaxation MRI images (T2 weighted images) were 
taken using a Multi Slice Multi Echo (MSME) sequence of PBS buffer, 
SiO2@QD, DOTA-SiO2@QD lacking the paramagnetic load and 
GdDOTA-SiO2@QD, at 400MHz and room temperature.  Notice the 
stronger effect of GdDOTA-SiO2@QD on T2 rather than T1. 
 
 
 
 
Table 1: T1 and T2 values of PBS buffer, SiO2@QD, DOTA-SiO2@QD 
lacking the paramagnetic load and GdDOTA-SiO2@QD, and various 
concentrations of GdDOTA from 0.39mM to 7.35mM at 400MHz and at 
room temperature.   
 
 
 
A similar approach is used to measure the transversal 
relaxation time T2 of the same samples. Spin-spin 
relaxation MRI images (T2 weighted images) were taken 
using a Multi Slice Multi Echo (MSME) sequence and are 
shown in Fig.2. Transversal relaxation times were 
determined by a plot of log (M/Mo) verses τ(ms).  The T2 
times were computing by fitting log(M/Mo) to a linear 
decay curve of log (M/Mo) = τ/T2. The T2 recovery curves 
are not shown; however the values are summarized in 
Table 1.  The transversal relaxation time of 4 µM 
GdDOTA-SiO2@QD is ~77 ms, much shorter than the T2 
of all other control samples where T2 is in the 345 ms to 
425 ms range. In this case, the presence of chelated Gd(III) 
linked to the silica surface produces a 4-fold decrease in T2 
compared to control solutions. As it is clear from Fig. 1, 
GdDOTA-SiO2@QD solutions have a stronger influence 
on the transversal relaxation time than on the longitudinal 
one.  
 
 
 
 
Figure 3: a) T1 and T2 MRI maps taken at various concentrations of 
GdDOTA-SiO2@QD ranging from 0.125 µM to 4 µM at 400 MHz and at 
room temperature.  During the same experiment, Gd-DOTA at a Gd(III) 
concentration of 390 µM and a phosphate buffer have also been imaged 
as a reference controls. b) Plots of 1/T1 and 1/T2 verses nanoparticle 
concentration are shown for the same samples. The slopes represent the 
relaxivity and correspond to r1=807.9 ± 15.4 mM-1s-1 and r2=3003.5 ± 
57.1 mM-1s-1. Ion relaxivities, i.e. relaxivity per Gd ion, are r1=17.9 ± 
0.34mM-1s-1 and r2=67 ± 1 mM-1s-1. 
 
 
It is worth noticing that only paramagnetic GdDOTA-
SiO2@QD provide a contrast in MR Images. All solutions 
lacking the paramagnetic load exhibit MRI images and 
relaxation times that barely depart from the buffer 
environment. Moreover, T1 and T2 values of 4 µM 
GdDOTA-SiO2@QD solutions are similar to relaxation 
values measured for unbound GdDOTA with a Gd(III) 
concentration of approximately 800-2500 µM.22 It may be 
tempting to conclude that there are about 200-600 
GdDOTA per SiO2@QD, however such extrapolation will 
prove to be incorrect as we will discuss later. Similar 
qualitative results were observed for GdDOTA-SiO2@Au, 
with nanocrystal cores of 5 and 10 nm diameter. MRI 
measurements presented so far indicate that GdDOTA-
SiO2@QD with a nanoparticle concentration in the µM 
range has the same contrast power than GdDOTA with 
Gd(III) concentration in mM range. 
To quantify this increase in sensitivity, MRI 
measurements were taken at various concentrations of 
contrast agent, and relaxivities were computed. GdDOTA-
SiO2@QD with nanoparticle concentration ranging from 
0.125µM to 4µM and unbound GdDOTA with Gd(III) 
concentration of 390 µM to 7150 µM were investigated 
simultaneously. The T1 and T2 maps are shown in Figure 
3a.  In the lower panels, we show the linear behaviors of 
the inverse relaxation times versus the contrast agent 
concentrations, 1/Ti ~ ri* C, i=1,2. The slopes ri represent 
the relaxivity of GdDOTA-SiO2@QD (GdDOTA, values 
in brackets) and correspond to r1=807.9 ± 15.4 (3.66 ± 
0.04) mM-1s-1 and r2=3003.5 ± 57.1 (3.8 ± 0.2) mM-1s-1 at 
400 MHz. 
 
 
 
 
Figure 4. Relaxivities of GdDOTA-SiO2@QD as a function of the proton 
Larmor frequency. The lines are guides for the eyes. The trend is similar 
to that of unbound GdDOTA. Notice however how the T2 relaxivity is 
always larger than the longitudinal one. 
 
 
 
 
Table 2: Relaxivity values at different fields measured at room 
temperature. In parenthesis is the value of the Gd(III) ion relaxivity. This 
is deduced from the measurement of Gd concentration per nanoparticles 
with ICP-MS. The bottom line serves as comparison with the Gd(III) ion 
relaxivity of unbound GdDOTA. 
 
So far, we have focused on the capability of 
GdDOTA-SiO2@QD to deliver a contrast signal using a 
400 MHz imaging system. However, most clinical 
scanners operate at 60 MHz. To investigate the behavior of 
our probes at 20 MHz and 60 MHz, we used a Bruker 
NMR Minispec.  The instrument does not afford imaging 
but allows the measurement of T1 and T2 from which 
relaxivities are deduced as described above. The 
longitudinal relaxivity r1 at 20 MHz and 60 MHz was 
determined to be r1=1932.0 ± 36.7 mM-1s-1 and r1=1018.6 
± 19.4mM-1s-1 respectively. The transversal relaxivity r2 
for 20 MHz and 60 MHz was r2=2483.6 ± 47.2 mM-1s-1 
and r2=2438.1 ± 46.3 mM-1s-1.  Relaxivities are 
summarized in Table 2 and in Fig. 4. Although we only 
have three data points, they seem to qualitatively follow 
the Nuclear Magnetic Relaxation Dispersion (NMRD) 
profile observed for unbound GdDOTA. 23, 24 In particular, 
r1 is strongly field-dependent. It decreases from ~2000 
mM-1s-1 at 20 MHz to ~ 800 mM-1s-1 at 400 MHz.  r2, as 
expected, exhibits a very slight increase with increasing 
fields. Notice how, at all frequencies, the transversal 
relaxivity of GdDOTA-SiO2@QD is larger than the 
longitudinal one. Therefore, GdDOTA-SiO2@QD appears 
to be a T2 contrast agent, even tough unbound GdDOTA 
affects mainly the longitudinal relaxation time. 
At the three field strengths investigated here, the 
relaxivities of GdDOTA-SiO2@QD reach values over 800-
3000 mM-1s-1, while the relaxivities of unbound GdDOTA 
ceils at 3-12 mM-1s-1. We determined by ICP-MS that there 
are approximately 45 chelated Gd ions per SiO2@QD in 
the samples presented above. Consequently, at 60 MHz for 
instance, every GdDOTA of the GdDOTA-SiO2@QD 
probe contributes for about 22.6 ± 0.4 mM-1s-1 to r1 and 
54.2 ± 0.3mM-1s-1 to r2. This represents a six-fold increase 
for r1 and twelve-fold increase for r2 compared to the value 
found for unbound GdDOTA at the same field strength.  
 
 
 
Figure 5 Relaxivity of 10 nm Au colloids coated with a paramagnetic 
silica shell at 20 MHz. The total size of the particles (including the silica 
shell) is about 15-18 nm . The particles contain more than 300 GdDOTA, 
thereby reaching relaxivity values close to those of organic dendrimers of 
generation N=7. 
 
 
To explore the cause of the increase in ion relaxivity, 
we initially speculated that the permanent electric dipole of 
QDs 25 may affect the local environment that chelated Gd 
experience through a dipole coupling. This ultimately 
perturbs the dynamics of water molecules in their 
neighborhoods. To test our assumption, QD nanoparticles 
were replaced with dipole-free cores such as gold. Thus, 
we developed the silanization of colloidal gold 
nanoparticles with 5 nm and 10 nm diameter (Fig.5). The 
smaller Au nanoparticles have the same size than 
CdSe/ZnS QD cores. At 20 MHz, we measured r1 = 2165.8 
± 41.2 mM-1s-1 and r2= 2709.9 ± 51.5 mM-1s-1 for silanized 
5 nm Au colloids with about 60 GdDOTA (determined by 
ICP-MS). For silanized 10-nm Au with over 320 
GdDOTA, we measured r1= 13510 ± 250 mM-1s-1 and r2= 
15815 ± 300 mM-1 s-1. The relaxivity values for GdDOTA-
SiO2@Au with Au cores of 5 nm are close to those 
obtained for GdDOTA-SiO2@QD solution. In addition, a 
dramatic increase in relaxivity occurs if 10 nm Au 
nanoparticles are used instead of 5 nm Au cores. Together, 
this suggests that the surface area of the nanoparticle rather 
than the physical nature of the underlying core is the key 
factor for increased relaxivities. 
To confirm the potentiality of our nanoprobe 
constructs, we perform preliminary dynamic contrast 
enhanced MR experiments in mice using a 1.5 T scanner. 
The nanoparticles were administered intravenously in the 
back of the mouse (100 µl, ~50 µM concentration in 
nanoparticles). Axial sections were collected at 8 seconds 
interval. Figure 6 represents two T1-weighted images taken 
at the level of the bladder before the injection (left) and 5 
minutes after the injection (right). The section of the 
animal is delineated by the thin white line in the left 
picture. The images have a similar contrast, except at the 
level of the bladder indicated by the arrow, where the 
signal increases with time; we attributed it to the clearance 
of the nanoparticles by the renal system. We observe 
accumulation of the nanoparticles as early as 300 s after 
injection. 
 
 
 
 
Figure 6 Axial T1 weighted image at the section of the bladder. The 
mouse body section is highlighted by the dashed white line in the left 
figure. Feature outside this line correspond to catheters and capillary 
tubes. The bladder is the pooch at the top-center of the mouse. Five 
minute after injection, nanoparticles start to accumulate in the bladder 
(right image, arrow). Notice how the contrast comes from only the lower 
part of the bladder, possibly indicating the sedimentation of the 
nanoparticles in the pooch. 
 
 
From preliminary data, we observe an enhanced contrast in 
the bladder, possibly in the liver, and in what seems to be a 
major blood vein. No contrast enhancement is seen in the 
kidneys. It is worth noticing that the mice do not seem to 
suffer from the injection of the silica-coated nanoparticles, 
indicating a good tolerance to these foreign contrast agents. 
 
 
 
 
4. Discussion 
 
We have presented a paramagnetic nanoprobe of 
about 10-15 nm in diameter that consists in an inner 
inorganic particle protected with an ultra-thin silica shell to 
which several chelated paramagnetic ions are covalently 
linked. Before discussing the properties of such probes as 
MRI contrast agents and the advantages of using a silica 
shell in biomedical applications, we first comment on the 
synthetic route to grow an ultathin paramagnetic silica 
shell around nanocrystals of different nature. 
 
Growing a nm-thin silica shell around Au colloids and 
other cores: The synthesis and use of semiconductor QDs 
coated with an ultra thin silica shell has been thoroughly 
described.14, 15 In this paper we have extended the 
procedure to embed Au colloids of 5 nm and 10 nm 
diameter into a thin silica shell. The synthesis of silica 
shells around Au cores has been detailed in Liz-Marzan et 
al. pioneering work.26 The authors used a 15 nm Au seed 
and showed how to grow thick shells (up to > 80 nm) over 
a period of several days.  
Two main issues in growing a silica shell around Au 
seeds are the avoidance of cross-linking between 
nanoparticles and the control of the polymerization rate. 
The latter calls for the use of an anhydrous solvent, while 
the former calls for diluted solutions of nanparticles. This 
is because polycondensation of methoxysilane into 
siloxane bonds is driven by hydrolysis and heat/basicity. 
We want neither of these conditions. First, citrate-
stabilized Au colloids are poorly soluble in solvents other 
than water (including aqueous buffers). Second we should 
dilute 20 ml of as-purchased 5 nm Au colloids (83 nM) in 
more than 500 mL of water to start with published 
protocols. The approach we develop here permits to 
silanize Au colloids in small volumes (<1-3 ml) at high 
nanoparticle concentration (> 1 µM for 5 nm Au). It is 
amenable to an easy scale-up and is applicable to the 
silanization of other inorganic cores such as iron oxide. 27 
Our silanization protocol for Au colloids calls for an 
exchange of the citrate capping ligands with a phosphine 
stabilizer (Bis(p-sulfonatophenyl)phenylphosphine), as 
described thoroughly in the literature. 16, 17 Phosphine-
stabilized Au colloids are soluble in buffers and water at 
concentrations ~50-100–fold higher than the original ones; 
we silanize the nanoparticles at these high concentrations. 
The phosphine capping is just an intermediate step to allow 
manipulation of Au colloids in water and preventing their 
aggregation. To grow the silica shell, phosphine groups are 
replaced with thiolate primers, specifically 
mercaptopropyltrimethoxysilane or MPS. Because of the 
strong affinity between thiols and gold surfaces, the 
capping exchange is fast (<20 min) and efficient. The 
methoxysilane or silanol groups of MPS act as an anchor 
molecule upon which the silica shell forms. The 
consolidation and polymerization of MPS into a siloxane 
or silica shell can be controlled by choosing weakly 
alkaline aqueous solutions (pH~7.5-8) instead of heat. 
While the shell is slowly forming, fresh MPS and PEG-
siloxane are incorporated into the shell. The shell growth is 
finally quenched by converting the remaining silanol 
groups into unreactive methyl groups. At this point 
silanized Au colloids can be purified from excess silane by 
dialysis, repeated runs in centricon 100 devices, and size-
exclusion column.  
The whole procedure for silanizing Au colloids takes 
about 3 hrs and is performed at particle concentration 
above ~ 1 µM for 5nm Au cores and above 0.1 µM for 
10nm cores. We found that the same protocol works for 
both sizes of Au colloids. There is no evidence of 
aggregation of particles during the silanization process. 
The plasmon peaks of citrate-Au solutions and silanized-
Au solutions are at the same wavelength (~524 nm vs ~526 
nm respectively). The UV-Vis spectrum of silanized Au 
solutions is stable for weeks, even though silanized Au 
solutions are stored at high concentrations in a 10 mM 
phosphate buffer. Gel electrophoresis mobility of silanized 
Au is qualitatively similar to that of silanized QD 
nanoparticles.  
 
Paramagnetic silica shell as a generic scaffold for 
multivalent contrast agents: The ability to grow silica 
shells around inorganic cores has several advantages: first 
the nanoparticles are extremely soluble in a wide variety of 
conditions (4<pH<11, and ionic strengths above 1M of 
phosphate buffer and 50 mM for buffers with divalent 
ions).  Silanized nanoparticles are also stable in 1x PBS 
buffer at concentrations exceeding 50 µM. Although 
viscous at these concentrations, the solutions flow without 
resistance through capillaries used for the administration of 
the contrast agent in small animals. Second, the overall 
size of the nanoparticles remains small since the silica 
shell only adds a few nm to the particle diameter. We 
estimate that the silica shell around the 5 nm Au cores is 
only 2 nm thick. This results in particle size of about 9 nm. 
Similarly, we estimate that the silica shell adds about 2-4 
nm to Au colloids of 10 nm in diameters, with a resulting 
total size of 15-18 nm. Finally, bioconjugation strategies to 
attach biomolecules to silica are well-developed. This is 
illustrated by the covalent linking of GdDOTA to the 
silanized nanoparticles. We link together the thiols of the 
silica shells with amines groups on the paramagnetic 
chelated species using the ubiquitous sulfo-SMCC 
(scheme 1). The linking protocol follows closely the one 
we develop to covalently bind DNA to silanized QD. 28, 29 
The design for this MRI contrast agent combines an 
outer paramagnetic shell with an inorganic core. It can 
generally be described as GdDOTA-SiO2@Particle. The 
great interest in such design is the possibility to select a 
material as the core particle that provides a signature 
orthogonal to the one provided by the paramagnetic 
GdDOTA-SiO2 shell. For example, the core provides an 
optical component (fluorescence), while the chelated 
paramagnetic ions linked to the outer shell contribute to 
MRI relaxivity. The strength of the design consists in the 
fact that the paramagnetic silica shell does not interfere 
with optical properties of the inorganic cores. For instance, 
the position of the plasmon peak of GdDOTA-SiO2@Au 
shifts by less than 2 nm compared to citrate-stabilized Au. 
Similarly, the UV-Vis absorption and fluorescence 
emission of GdDOTA-SiO2@QD are virtually similar to 
those of TOPO-capped QD. Although detailed 
investigations of fluorescence properties have not been 
performed in detail, side-to-side comparison of QD and 
GdDOTA-SiO2@QD excited with a hand-held UV lamp 
shows that both solutions have fluorescence properties 
(color and intensity) undistinguishable to the naked eye. 
This approach, where optical and MRI properties arise 
from physically separated and weakly interacting entities, 
present several advantages over other approaches devised 
to make multivalent probes. For instance, attempts to dope 
the shell of fluorescent core/shell CdSe/ZnS nanoparticles 
with Mn impurities produce multimodal nanoparticles with 
quenched fluorescence and a relatively weak magnetic 
contribution.  
Achieving high relaxivities does not require the use of 
an inorganic core of a specific nature, because the MRI 
contrast power is carried only by the paramagnetic silica 
shell. In fact, it may be possible to optimize the design and 
reach even higher relaxivity values by other combinations 
of lanthanide ions, chelators and inorganic nanoparticles.  
Any inorganic core that can be embedded into silica can be 
used as seed for high relaxivity contrast agents.  This 
includes CdSe/ZnS, CdTe, Au, Ag, and any oxide 
nanocrystals, such as very small superparamagnetic iron 
oxide nanoparticles. 27 
 
Mechamisms responsible for relaxivity enhancement: 
In this study, we found that GdDOTA-SiO2@QD and 
GdDOTA-SiO2@Au with a diameter of about 8-10 nm (5 
nm cores + 2 nm silica shell) exhibit relaxivities in excess 
of r1 ~1000-2000 mM-1s-1 and r2 ~ 3000 mM-1s-1 and are 
detectable at ~100 nM concentrations. One obvious reason 
for this enhanced relaxivity is the number of GdDOTA 
molecules that decorate the silica surface. Chemical 
analysis indicates that about 45-50 GdDOTA are covering 
the silica surface of SiO2@Au with 5 nm cores. More than 
250-300 GdDOTA were measured around SiO2@Au with 
10 nm cores. As a result, relaxivities skyrocketed to 
~16’000 mM-1s-1 and the detection limit plunged in the 10 
nM range.  
While the number of paramagnetic chelated ions is 
certainly the major factor in enhancing the total relaxivity, 
more subtle effects may also contribute to it. They 
manifest themselves by increasing the contribution of 
every individual GdDOTA to the total relaxivity. To see 
this, the total relaxivities of the samples is divided by the 
number of GdDOTA and converted into an ion relaxivity. 
This translates into T1 and T2 ion relaxivities at 60 MHz of 
~ 23 mM-1s-1 and 54 mM-1s-1 for GdDOTA-SiO2@P and 
only 3-5 mM-1 s-1 for unbound GdDOTA.  
Increased ion relaxivities are expected when 
GdDOTA is constrained in its rotational motion. This is 
observed for macromolecular conjugates.10 It has also been 
observed in a recent study where paramagnetic lipids were 
desorbed around a QD nanoparticle and relaxivities in the 
range of 2000 mM-1s-1 at 60 MHz were measured. 30 It was 
determined that about ~150 GdDOTA-lipids were 
surrounding the nanoparticle scaffold. Consequently, at 60 
MHz, every Gd ion in the lipid payload was contributing 
by about 12 mM-1s-1 to the spin-lattice relaxivity r1 and by 
about 18 mM-1s-1 to the spin-spin relaxivity r2. It was 
mainly assumed that the increase in ion relaxivity came 
from the reduced tumbling rate of GdDOTA due to its 
covalent linking to a higher molecular weight 
macromolecule and the consequent increase in its 
rotational correlation time. 
Our probes are quite similar to these, except that the 
paramagnetic lipid coat is replaced with a thinner 
paramagnetic silica shell. Yet, this change alone seems to 
affect the ion relaxivities. The values for the paramagnetic 
silica shell are 2 to 3 times higher than the values obtained 
with the paramagnetic lipid. As a result, our probes reach 
the same sensitivity with twice to three times less Gd(III) 
load. Although the rotational correlation time may be 
slightly different for these two systems, it is unlikely that it 
alone accounts for this large difference in relaxivity. We 
believe that a second reason for the increase in ion 
relaxivity comes from the very hydrophilic environment 
around GdDOTA provided by the silica shell. Silica is 
much more hydrophilic than lipids. It is likely that it 
generates a denser water solvation shell around the 
nanoparticle which forces more protons to interact with 
GdDOTA. We rule out that the high permanent electric 
dipole of the SiO2@QD can affect the dynamic of water 
proton markedly, because the replacement of a QD core 
with a dipole-free Au particle of similar size produces a 
similar increase in ion relaxivity.  
It is instructive to observe that ion relaxivities for 
GdDOTA-SiO2@P are very close to those obtained for 
high generation organic dendrimer-GdDOTA (N>7) where 
ion relaxivities reach a plateau at 35 mM-1s-1 and 43 mM-1s-
1 respectively.31 In general, data for GdDOTA-SiO2@P 
suggest that their MRI properties can be satisfactorily 
described within the framework of the classical relaxation 
theory.10 
 
Relaxivity of GdDOTA-SiO2@nanoparticles vs other 
contrast agents:  Nanoparticles embedded into 
paramagnetic GdDOTA-SiO2 shells reach relaxivities of a 
few thousands mM-1s-1 well in excess of the few, to a few 
tens mM-1s-1 observed for individual GdDOTA.10 They 
surpass the relaxivity of hyperbranched dendrimers of 
generation N=5. 32 In fact, their relaxivities are surpassed 
only by the relaxivity of highly complex and branched 
organic dendrimers of generations N≥7 31 and iron oxide 
nanoparticles with core size above 20-40 nm.6 Our probes 
compared favorably with the most promising new types of 
MRI contrast agent technology based on ultrasmall iron 
oxide nanoparticles. 33-35 For instance, a recent report 
indicated that Au-coated iron oxide nanoparticles with a 
size of 19 nm have ion relaxivities of only 3 mM-1s-1 in the 
30-50 MHz range.35 Considering that there are a few 
thousand Fe ions per nanoparticle, this translates into total 
relaxivities estimated in the ~10’000-20’000 mM-1s-1 range. 
At this size range however, the surface chemistry of iron 
and iron oxide is not yet well developed. Nanoparticles are 
often solubilized by ligand exchange,33, 34 although such 
approach is unlikely to have widespread use in vivo 
because of the non-covalent nature of the passivating 
bonds. Cross-linked, stable and robust shells are necessary. 
Silica shells,27 Au shells35 and clustering into polymeric 
micelles13 have been investigated. However, owing to the 
poor control of surface chemistry, extensive aggregation is 
often observed for several of these formulations making 
them unsuitable for in vivo imaging. 
Our MRI probes exhibit a very high solubility and 
stability. They also represent a compromise between very 
high relaxivity values (> 100’000 mM-1s-1) obtained with 
large iron oxide particles (> 50-200 nm) and small 
“protein-like” sizes of branched dendrimers with 
relaxivities around 1000 mM-1s-1. 32  In addition, our MRI 
probes can be made in a few hours, in an Eppendorf tube 
using water as main solvent and a benchtop centrifuge for 
purification. The design has considerable potential for 
scale-up and plenty of room for tailoring the surface to 
specific biological applications (linking of targeting agent 
for instance). 
 
Advantages of a paramagnetic silica shell coating in 
biology: Bare inorganic nanocrystals tend to aggregate in 
aqueous solutions and adsorb plasma or other proteins 
through non-specific interactions. To prevent their 
aggregation and tailor their surface properties, nanocrystals 
must be stabilized and embedded into a biocompatible and 
robust shell. Silica presents several advantages over 
polymer-based shells. Unlike polymers, silica is not 
subjected to microbial or macrophage attack and it neither 
swells nor changes shape and porosity with changing pHs. 
Silica is chemically inert and therefore does not influence 
the redox reaction of the core surface. Furthermore, the 
chemistry to functionalize silica is well-developed. It is 
straightforward to introduce thiols, amine or carboxylic 
groups onto a silica surface. The groups can be further 
derivatized with targeting biomolecules using established 
bioconjugation techniques. 20 Finally, it is much easier to 
control the polymerization of siloxane into silica (and 
hence the size of the silica shell) than it is to control the 
thickness of a polymer-based coating. For example, FCS 
and dynamic light scattering measurements indicated that 
while silica-coated 5 nm Qdots have a hydrodynamic 
radius of 9-11 nm, polymer-embedded 5 nm Qdots have a 
hydrodynamic radius close to 30 nm 36 and 19 nm Au-
coated iron oxide close to ~250 nm. 35 
Silica has other advantages over polymeric nanoparticles 
that have emerged in recent live cell studies: low toxicity. 
Silica-coated nanoparticles exhibit much smaller 
cytotoxicity than polymer-coated nanoparticles.37 Even 
more remarkable, silica-coated nanoparticles were shown 
to have negligible perturbation on the gene expression 
patterns of lung and skin epithelials cells. 38 This suggests 
that silica-coated nanoparticles pose minimal interference 
with the normal physiology and metabolism of these cells 
lines. Because silica-coated nanoparticles can be 
functionalized with a wide array of targeting biomolecules, 
15, 28, 29 they can be biologically programmed to recognized 
critical phosphorylation sites, proteases and nucleases, 
motor proteins, or surface receptors on organelles such as 
the cell nucleus. 39 These nanoparticles may play a key role 
in cell biology for deciphering molecular pathways. 
Toxicity studies at the gene expression level of silica-
coated nanoparticles on other cells lines, tissues or animal 
models has not been investigated so far and are 
undoubtably an emerging research area.  
 
Preliminary in vivo assays – successes and pitfalls 
In a series of early in vivo assays, the contrast agent 
based on paramagnetic silanized nanaoparticles was 
injected into live mice. We injected about 6x1015 particles 
(i.e. ~200 µl at 50 µM) and did not observe adverse effects 
on the health of the animals. In fact, the vast majority of 
silanized particles are excreted into the bladder. In 
dynamics contrast enhanced studies, we observe the 
accumulation of the nanoprobes in the bladder within 
minutes of the injection. We do not observe a contrast 
enhancement from other organs, indicating that the large 
majority of the nanoprobes are filtered out by the renal 
system. 
The fact that silanized nanoparticles are not taken up 
by the different organs in a significant manner is a positive 
sign, in particular in view of the fears of potential toxicity 
of the nanomaterials. In contrast, low retention time is the 
bloodstream represents a potential pitfall many 
applications including for angiogenesis, i.e. the formation 
of new blood vessels. However, both specific uptake and 
retention time can be implemented or improved by 
tailoring the surface chemistry of nanoparticles, for 
instance by grafting targeting peptides or longer PEG 
chains.  
At this stage, it is still an open question whether 
paramagnetic silica nanoparticles will have the ability to 
transverse the extracellular matrix surrounding blood 
vessels and microvsculatures, and if they will have the 
ability to recognize cancer cells and delineate the contours 
of a tumor. It is likely that both size and surface 
composition will play key roles for such endeavors. The 
discussion above highlights the need of a tailored surface 
chemistry, but neglect to mention the importance of the 
“size” parameter. Indeed, if the probes are too big, they 
will have a reduced ability to diffuse in tumoral 
microvasculature and transverse the extracellular matrix, 
as they have a limited ability to cross cellular membranes. 
Although the ideal size of a probe is not known, we 
hypothesize that probes with sizes in the 10-20 nm range, 
as the ones we developed and with an appropriate surface 
chemistry, represent the best candidates since they mimic 
the size of therapeutic antibodies.  
In order to use our silica-coated nanoparticles for 
angiogenesis or other targeted applications (stem cell 
tracking, where a small number of parent cells can be 
labeled, implanted and their progeny followed in vivo, 33 
guided surgery, …), the total relaxivity and contrast power 
of our probes will have to be enhanced even further. An in-
depth comparison with conventional contrast agents 
(Magnevist, Dotarem, …) is underway. We estimate that 
we need to increase the number of GdDOTA from ~50 to 
~500 in the Qdots probes, to have sufficient contrast 
enhancement for in vivo applications. This challenge 
seems feasible. 
 
 
4. Conclusions  
 
We have described a strategy to embed inorganic 
nanoprobes into a paramagnetic silica shell. The shell is 
rendered paramagnetic by covalently linking GdDOTA to 
its surface. Once attached to the surface, each of these 
contrast agent units exhibit T1 and T2 ion relaxivities at 
clinical fields that are respectively 9 and 18 times larger 
than the ion relaxivities of unbound GdDOTA.  We 
provide evidence that the increase is not related to the 
nature of the inorganic core but most likely to the fact that 
GdDOTA are bound to a hydrophilic silica surface which 
reduces their rotational motion. 
What matters for imaging purposes is not primarily 
the ion relaxivity of a contrast agent, but its total relaxivity. 
Similar to the case of dendrimeric polymers, multiple 
GdDOTA can be anchored onto the surface of a single 
silica nanoparticle. Since the ion relaxivity is additive, we 
have measured T1 and T2 relaxivitites at room temperatures 
and at clinical fileds in the order of  1000-3000 mM-1 s-1 
for GdDOTA-SiO2@Particle with particle cores of 5 nm, 
resulting from the contribution of ~ 50 GdDOTA.  If the 
particle cores are 10 nm, the surface area of silica shells 
permits the linking of ~250-300 GdDOTA. Remarkably, 
these latter probes exhibit relaxivities in excess of 15000 
mM-1s-1 at room temperature and clinical fields. 
The paramagnetic silica shell has been grown around 
semiconductor and metallic nanoparticles. There are 
however no restriction in the use of the core material. It 
may be envisioned to grow a GdDOTA-SiO2 around a 
(superpara)magnetic core such as small SPIO Fe3O4 or 
Fe2O3. In that configuration, perturbation in the dynamic 
response of water protons will come from the presence of 
the paramagnetic GdDOTA-SiO2 shell and from the inner 
SPIO cores. We expect such systems to present even 
higher relaxivities values that the ones obtained here.  
Preliminary in vivo tests indicate that paramagnetic 
silica-coated nanoparticles provide a contrast enhancement 
in MRI, as evidenced by the signal coming from their 
accumulation in the bladder. However, higher sensitivities 
will be needed to obtain valuable information in MRI on a 
peculiar biological issue.  
The design of our probe allows its straightforward 
conversion into a PET probe. For that, only a handful of 
DOTA have to be loaded with a radioisotope (i.e. 64Cu) 
instead of Gd(III). The overall probe will maintain a 
unique surface chemistry. However since PET sensitivity 
far exceeds MRI sensitivity, it is possible to test basic 
properties of the probes, such as their potential leakage 
from the vascular system, their non-specific uptake by 
different organs, or their ability to recognize tumors. These 
studies, currently underway, will provide powerful 
complementary information on the compatibility and 
utility of inorganic nanoprobes for in vivo imaging. 
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